FDA gives more time for electronic safety reporting
This article was originally published in Scrip
Executive Summary
The FDA on 26 May said it was delaying until 8 September compliance with a requirement to electronically submit postmarketing individual case safety reports (ICSRs) of adverse events linked to drugs and biologics.